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We designed a study to investigate the molecular epidemiology of group A streptococcal (GAS) and group C
and G streptococcal (GCS and GGS) disease in Fiji, a country which is known to have a high burden of
streptococcal disease. Molecular typing of the N-terminal portion (emm typing) of the M protein was performed
with 817 isolates (535 GAS and 282 GCS/GGS). We also performed genotyping of the C-repeat region in 769
of these isolates to identify J14 sequence types. The profile of emm types for Fiji was very different from that
found for the United States and Europe. There were no dominant emm types and a large number of overlapping
types among clinical disease states. Commonly found GAS emm types in industrialized countries, including
emm1, emm12, and emm28, were not found among GAS isolates from Fiji. Over 93% of GAS isolates and over
99% of GCS/GGS isolates that underwent J14 sequence typing contained either J14.0 or J14.1. Our data have
implications for GAS vaccine development in developing countries and suggest that a vaccine based upon the
conserved region of the M protein may be a feasible option for Fiji and potentially for other tropical developing
countries.
The group A streptococcus (GAS) is an important cause of
morbidity and mortality globally, with variation in disease bur-
den between populations (9). A greater burden of GAS disease
occurs in developing countries, particularly those located in the
tropics, than in industrialized nations (9). The spectrums of
GAS disease also differ between developed and developing
countries. In many developing countries, GAS impetigo is of-
ten endemic, with resultant high rates of acute poststreptococ-
cal glomerulonephritis, acute rheumatic fever, and rheumatic
heart disease leading to at least 200,000 deaths annually, and
the burden of invasive disease has probably been underesti-
mated (9, 43). In industrialized countries, a massive number of
cases of GAS pharyngitis leads to significant economic impact
(27) and invasive disease leads to a significant number of
deaths (25, 26).
The molecular epidemiologies of GAS disease appear to
differ between industrialized and developing nations, although
there is a paucity of data from developing nations (5, 9). There
are a number of different methods used to characterize GAS,
with sequence typing of the 5 N-terminal end of the M protein
gene (emm) the most widely used (3, 17, 18). There have been
recent large epidemiologic studies that have used emm se-
quence typing to investigate the molecular epidemiology of
GAS pharyngitis and invasive GAS disease in industrialized
nations, most notably in the United States, Canada, and Eu-
rope (16, 26, 37) (R. R. Tanz, S. T. Shulman, W. Kabat, E.
Kabat, E. Cederlund, D. Patel, Z. Li, V. Sakota, J. B. Dale, and
B. Beall, presented at the XVIth Lancefield International Sym-
posium on Streptococci and Streptococcal Diseases, Palm
Cove, Queensland, Australia, 2005). Far fewer studies have
been conducted in developing nations. The limited available
data suggest that numerous new emm types and subtypes have
been discovered that have not previously been observed in
industrialized countries (40, 45), that the diversity of emm
types in developing countries is greater than that in industri-
alized countries (23, 32–34, 40, 45), and that the majority of
isolates are of emm types traditionally associated with impe-
tigo, irrespective of the clinical site of recovery of the isolates
(5, 6, 23, 33, 40).
Molecular epidemiologic data have implications for vaccine
design. Although a number of antigens have shown promise as
potential vaccine candidates, only one vaccine, a 26-valent
M-protein-based vaccine, has reached clinical trials in recent
times (15, 24). Serotypes for this vaccine were chosen if they
were known to be common causes of invasive GAS disease or
uncomplicated pharyngitis in the United States or if they were
associated with rheumatic fever in classical studies from the
United States in the mid-20th century (14). While this vaccine
is likely to be efficacious in the United States, concerns have
been raised about the transferability of this vaccine to devel-
oping-country settings (8).
Alternative approaches to a multivalent vaccine strategy in-
clude the development of a conserved-epitope vaccine. A num-
ber of conserved epitopes have been identified and are under
investigation, including some within the portion of the M pro-
tein closest to the cell wall (the C-repeat region) which appear
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to be relatively conserved (2, 11, 31, 36). An example is the J8
peptide, a B-cell epitope, contained within the larger sequence
J14 (named J14.0 in this article for clarity) (28, 29). Following
the discovery of J14.0, a number of J14 sequence types have
been identified (47). To date, across all C-repeat regions, there
have been 55 different J14 sequence types described, which
have been named in the order that they have been discovered
(J14.0 to J14.54) (47). Typing of the C-repeat region by the J14
sequence type of GAS has been employed previously (47). J14
sequence type is relevant to J8 because antibodies raised
against J8 in mice provide cross-protective immunity against
GAS isolates containing J14.0 and J14.1 (Michael Batzloff,
Queensland Institute of Medical Research, unpublished data).
Antibodies raised against the J14.0 peptide in mice have been
shown to opsonize GAS strains belonging to a variety of emm
subtypes that contain J14 sequences other than the J14.0 se-
quence type, including J14.2 (47).
Group C streptococci (GCS) and group G streptococci
(GGS) are emerging infectious agents, particularly as a cause
of invasive disease and of epidemic pharyngitis (19, 35, 48). We
have observed higher than expected rates of invasive GCS/
GGS in Fiji, as well as high pharyngeal carriage among school
children (43). There is also some evidence to suggest that these
organisms may play a role in the pathogenesis of acute rheu-
matic fever and poststreptococcal glomerulonephritis (13, 30).
There are very few data regarding emm sequence typing of
GCS/GGS and no available data regarding sequence typing of
the C-repeat region of these organisms (22).
We designed a study to investigate the molecular epidemi-
ology of GAS and GCS/GGS disease in a tropical setting
known to have a high burden of invasive, pharyngeal, and
impetiginous streptococcal disease (42–44). Because of the
implications for vaccine development, we included molecular
typing of both the 5 end of the M protein (emm sequence
typing) and the C-repeat region of the M protein (J14 se-
quence typing).
MATERIALS AND METHODS
Source of isolates. Eight hundred and seventeen beta-hemolytic streptococcal
isolates collected in a series of population-based studies underwent emm se-
quence typing, of which 535 were GAS and 282 were GCS/GGS (Table 1). We
analyzed GCS and GGS isolates as a single subspecies, Streptococcus dysgalactiae
subsp. equisimilis, because all of the GCS and GGS isolates shared the same large
colony morphology and because 16S rRNA gene sequencing was used to avoid
misclassification where necessary (23, 46). Sterile site isolates were collected in
an all-ages prospective surveillance study of invasive streptococcal disease con-
ducted in the Colonial War Memorial Hospital in Suva, Fiji, over a 2-year period
(December 2005 to November 2007) (43). Pharyngeal isolates were collected in
a 10-month prospective cohort survey of school children aged 5 to 15 years in
four schools in 2006 (42). Swabs of the pharynx were taken from asymptomatic
children (carriage) and from children who complained of a sore throat. Over the
same time period, 455 children also had a swab taken of any crusted or purulent
impetigo lesions noted at repeated skin examinations every 2 months (total of six
visits).
Laboratory methods. Swabs were collected, transported, and cultured by con-
ventional methods, as previously described (21, 41). All beta-hemolytic isolates
were transported to the Queensland Institute of Medical Research for genotyp-
ing of the emm region and the C-repeat region of the M protein. emm sequence
typing was performed using the standard methodology developed by the U.S.
Centers for Disease Control and Prevention (CDC) (http://www.cdc.gov/ncidod
/biotech/strep/strepindex.htm), and novel emm nucleotide sequences were sub-
mitted to the Streptococcal Reference Laboratory at the CDC, where they were
assigned a sequence type or subtype by the laboratory moderator. Sequences
were generated for the C-repeat region using the same method used for emm
typing and were translated into a single-letter amino acid code using the ExPASy
online translation tool (http://ca.expasy.org/tools/dna.html). J14 sequence types
were assigned to each bacterial strain based on the amino acid sequence corre-
sponding to the conserved region of the M protein. Novel sequences were
checked by resequencing of the region. C-repeat regions were named by con-
vention (C3 being closest to the cell membrane), although we added C1-1 and
C1-2 for isolates that contained more than three C-repeat regions.
Statistical analysis. emm sequence type and emm subtype distribution were
analyzed by Lancefield group, by specimen type, by clinical disease profile, and
by acquisition over time. We measured the variation of the number of emm
sequence subtypes using Simpson’s index of diversity; the higher the index, the
greater the probability that any two isolates will be of different sequence types
(12, 38). When comparing proportions of isolates belonging to individual GAS
emm subtypes with site of specimen and severity of impetigo, we calculated
relative risks using standard methods. We assessed the number of isolates in our
study that belonged to emm types that are included in the 26-valent M protein-
based GAS vaccine currently under clinical investigation (24). We combined the
J14 sequence types in the C3, C2, and C1 regions to create “overall” J14 C-repeat
types for each isolate (for example, an isolate with J14.1 in C3, J14.2 in C2, and
J14.4 in C1 had an overall J14 C-repeat type of J14.1-J14.2-J14.4). The statistical
package STATA version 10.0 (Stata Corporation, College Station, TX) was used
to analyze the data.
Ethical approval and consent. Ethical approval was obtained from the Fiji
National Research Ethics Review Committee, the Fiji National Health Research
Committee, the University of Melbourne Human Research Ethics Committee,
and the Queensland Institute of Medical Research Human Research Ethics
Committee. Children were enrolled only if written consent from a parent or
guardian was obtained. Children aged 10 years or older were enrolled only if
written assent by the child was also obtained.
RESULTS
Of the 817 beta-hemolytic streptococcal isolates included in
the study, there were 105 different emm sequence types and
122 emm sequence subtypes. There were no emm sequence
subtypes that were shared between GAS and GCS/GGS iso-
lates.
GAS emm sequence typing. Among the 535 GAS isolates,
there were 67 emm types and 74 emm subtypes. There was high
diversity of GAS emm subtypes overall (Simpson’s index of
diversity, 97.1; 95% confidence interval [CI], 96.8 to 97.5), with
the greatest diversity occurring in invasive isolates (index, 98.2;
95% CI, 97.2 to 99.3), followed by pharyngeal isolates (index,
97.9; 95% CI, 97.2 to 98.5) and then impetigo isolates (index,
TABLE 1. Numbers of isolates that were emm typed by clinical
disease type and by beta-hemolytic streptococcal groupa
Disease type BHS group No. ofswabs
No. of
isolates
available
No. of
isolates
emm
typed
Invasive disease GAS NA 64 55
GCS/GGS NA 18 12
Throat carriage GAS 665 40 40
GCS/GGS 126 120
Culture-positive
sore throat
GAS 678 61 61
GCS/GGS 120 113
Impetigo GAS 563 449 439b
GCS/GGS 39 37b
a BHS, beta-hemolytic streptococcal; NA, not applicable.
b There were 108 children who had more than one impetigo swab taken at each
visit, and only one of two isolates was counted when the same emm subtype was
found in an individual at the same visit, meaning that there were 379 GAS
isolates and 37 GCS/GGS isolates included in the final analysis.
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96.2; 95% CI, 95.6 to 96.8). There was one entirely new emm
sequence type (st465) discovered in a throat carriage swab, and
four new emm subtypes (emm39.4 and emm60.7 from pharyn-
geal swabs and emm89.11 and emm93.4 from impetigo lesions).
Among the 101 pharyngeal GAS isolates that underwent
emm sequence typing, there were 45 emm types and 46 emm
subtypes. There were no apparent dominant emm subtypes
among the pharyngeal isolates (Fig. 1). There were 14 emm
subtypes (30%) that were common to both throat carriage and
sore throat (n  47, 46.5%), and of these, none was signifi-
cantly associated with carriage or sore throat.
There were 52 emm types and 56 emm subtypes recovered
from 379 GAS impetigo lesions (Fig. 1). Of all GAS impetigo
cases, 137 (36.1%) were classified as being moderate or severe
impetigo (defined as the presence of more than five vesiculo-
pustular impetigo lesions). Of the 56 emm subtypes, there were
two emm subtypes that were statistically significantly associated
with moderate or severe impetigo: emm25.0 (relative risk
[RR], 2.5; 95% CI, 1.2 to 5.1) and emm74.0 (RR, 10.1; 95% CI
1.9 to 53.8).
When impetigo and pharyngeal GAS isolates were pooled,
there were 60 emm types and 66 emm subtypes among 480
isolates (Tables 2, 3, and 4). Of these, there were 36 emm
subtypes (55%) that were common to both sites (n  383,
79.8%), 20 (30%) that were found only in isolates from impe-
tigo lesions (n  81, 16.9%), and 10 (12%) that were found
only in isolates from the pharynx (n  16, 3.3%). Therefore,
84.2% of all isolates found in isolates from the pharynx be-
longed to emm subtypes that were also found in isolates from
impetigo lesions. Four emm subtypes were statistically signifi-
cantly associated with isolation from the pharynx (emm86.2,
emm92.0, st6030.1, and stNS554.1), and one was significantly
associated with isolation from impetigo lesions (emm70.0) (Ta-
ble 2).
Of the 55 GAS isolates from sterile sites, there were 37 emm
types and 38 emm subtypes. There were no clearly dominant
emm subtypes causing invasive disease (Fig. 1). There were
seven emm subtypes causing invasive disease that were not
found in skin or pharyngeal isolates (n  9, 16%). Forty-three
of the emm subtypes causing invasive disease (78% of isolates)
were also found in impetigo lesion isolates.
Overall, 12 of the 74 emm subtypes recovered in our study
are included in the 26-valent GAS vaccine currently undergo-
ing clinical trials, representing 137 isolates overall (25.6%;
95% CI, 22.0 to 29.5). The highest proportion of isolates in-
cluded in the vaccine was found in invasive GAS isolates
(32.7%; 95% CI, 20.7 to 46.7), followed by carriage (30%; 95%
CI, 16.6 to 46.5), sore throat (26.2%; 95% CI, 15.8 to 39.1), and
impetigo (24%; 95% CI, 19.8 to 28.6) isolates.
FIG. 1. The 25 most common emm subtypes as proportions of total isolates causing GAS and GCS/GGS disease, grouped by GAS isolates
found in the pharynx (A), GAS isolates causing impetigo (B), GAS isolates causing invasive disease (C), and GCS and GGS isolates found in the
pharynx (D). (Black bars represent emm subtypes that are included in the current experimental multivalent GAS vaccine, while white bars
represent those emm subtypes that are not included; the dotted line represents the cumulative percentage of all isolates). The 25 most common
emm subtypes contributing to pharyngeal isolates are shown in panel A (there was a further emm subtype, st854.1, that was ranked 25th equally);
these 26 emm subtypes accounted for 78.2% of all pharyngeal isolates, with 21 other emm subtypes contributing to the remaining 21.8%. The 25
most common emm subtypes contributing to impetigo isolates are shown in panel B (there were a further three emm subtypes, emm74.0, emm123.0
and st2147.0, that were ranked 25th equally); these 28 emm subtypes accounted for 86% of all impetigo isolates, with 28 other emm subtypes
contributing to the remaining 14%. The 25 most common emm subtypes contributing to invasive isolates are shown in panel C (there were a further
13 emm subtypes, emm82.1, emm86.2, emm87.0, emm101.0, emm104.0, emm105.0, emm113.0, emm116.1, emm123.0, st2037.0, st2147.0, st6030.1.0,
and stD631.0, that were ranked 25th equally); these 38 isolates accounted for 100% of all isolates. The 25 most common emm subtypes contributing
to GCS and GGS pharyngeal isolates are shown in panel D (there were a further six emm subtypes, st839.0, stC922.0, stG2574.0, stG5420.0,
stG652.1, and stGM220.0, that were ranked 25th equally); these 31 emm subtypes accounted for 93.6% of all pharyngeal isolates, with 15 other emm
subtypes contributing to the remaining 6.4%.
TABLE 2. emm subtypes recovered from GAS from both the
pharynx and impetigo lesions
emm
subtypea
Pharynx
(n  85)
Impetigo
(n  298)
Total
(n  383)
n % n % n %
emm11.0 2 2.4 21 7.0 23 6.0
emm25.0 2 2.4 24 8.1 26 6.8
emm25.1 3 3.5 5 1.7 8 2.1
emm33.0 5 5.9 26 8.7 31 8.1
emm42.0 1 1.2 2 0.7 3 0.8
emm44.0 4 4.7 5 1.7 9 2.3
emm49.0 1 1.2 6 2.0 7 1.8
emm54.1 2 2.4 3 1.0 5 1.3
emm56.0 3 3.5 14 4.7 17 4.4
emm58.0 2 2.4 1 0.3 3 0.8
emm69.1 2 2.4 15 5.0 17 4.4
emm70.0** 2 2.4 40 13.4 42 11.0
emm71.0 2 2.4 5 1.7 7 1.8
emm74.0 2 2.4 5 1.7 7 1.8
emm75.1 1 1.2 1 0.3 2 0.5
emm76.4 3 3.5 12 4.0 15 3.9
emm77.0 1 1.2 2 0.7 3 0.8
emm82.1 2 2.4 12 4.0 14 3.7
emm86.2* 5 5.9 3 1.0 8 2.1
emm89.0 3 3.5 12 4.0 15 3.9
emm92.0* 6 7.1 6 2.0 12 3.1
emm93.3 1 1.2 22 7.4 23 6.0
emm101.0 4 4.7 6 2.0 10 2.6
emm105.0 3 3.5 6 2.0 9 2.3
emm109.1 1 1.2 1 0.3 2 0.5
emm112.2 1 1.2 2 0.7 3 0.8
emm116.1 1 1.2 2 0.7 3 0.8
emm122.2 1 1.2 1 0.3 2 0.5
emm123.0 2 2.4 5 1.7 7 1.8
st2147.0 2 2.4 5 1.7 7 1.8
st6030.1* 6 7.1 9 3.0 15 3.9
st854.1 2 2.4 10 3.4 12 3.1
stCK401.0 1 1.2 1 0.3 2 0.5
stD631.0 1 1.2 1 0.3 2 0.5
stNS1033.0 1 1.2 4 1.3 5 1.3
stNS554.1* 4 4.7 3 1.0 7 1.8
a *, subtypes that were significantly associated with recovery from the pharynx were
emm 86.2 (RR, 6.7, 95% CI, 1.6 to 27.4), emm92.0 (RR, 4; 95% CI, 1.3 to 12.1), st6030.1
(RR, 2.7; 95% CI 1.0 to 7.3), and stNS554.1 (RR, 5.3; 95% CI, 1.2 to 23.5); **, subtype
that was associated with impetigo was emm70.0 (RR, 5.1; 95% CI, 1.3 to 20.8).
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GCS and GGS emm sequence typing. There were 38 emm
types and 48 emm subtypes found among 282 GCS/GGS iso-
lates. There were eight emm subtypes that were common to
both GCS and GGS, 19 that were found in GCS isolates only,
and 21 that were found in GGS only. There were six new emm
types that accounted for 21 isolates: stCQ343, stCN204,
stGL265, stG228, stGM203, and stGM220. There were five new
emm subtypes, all individual isolates: emm12.45, stG245.1b,
stC5345.3, stC749.0, and stC839.3.
Of the 270 isolates from pharyngeal or impetigo swabs, all
but two emm subtypes out of 48 emm subtypes (stG643.1 and
stG5240.0, one isolate each) were found in isolates from the
pharynx, with 20 emm subtypes shared between isolates from
the pharynx and skin (n  173, 64.1%) and 26 emm subtypes
found only in isolate from the pharynx (n 95, 35.2%). There-
fore, of the 37 GCS/GGS isolates from impetigo lesions, 35
(95%) were of emm subtypes also found in isolates from the
pharynx. Of the 12 isolates from sterile sites, there were nine
emm subtypes, and all of these subtypes were also found in
isolates from both the pharynx and impetigo lesions.
Pharyngeal isolates accounted for 233 of all GCS/GGS iso-
lates recovered on the study, and of these there were 46 emm
subtypes. There were six dominant GCS/GGS emm subtypes,
accounting for 49.8% of all GCS/GGS pharyngeal isolates (Fig.
1). There were 20 emm subtypes (43%) that were found in both
sore throat cases and carriage swabs (n  189, 81.1%).
C-repeat region sequence typing. Of the 817 isolates in the
study, 769 (94.1%) underwent successful sequencing of the
C-repeat region for J14 sequence types (521 of 535 GAS iso-
lates, 97.4%; and 248 of 282 GCS/GGS isolates, 87.9%). The
majority of GAS isolates contained three C repeats (n  477,
91.6%), with 40 GAS isolates containing two C repeats and 4
isolates containing only one C repeat (Fig. 2). More than half
of the GCS/GGS isolates contained four C repeats (n  136,
54.8%), with 57 isolates containing three C repeats (23%), 43
isolates containing five C repeats (17.3%), 11 isolates contain-
ing two C repeats (4.4%), and 1 isolate containing one C
repeat (pharyngeal isolate, stG653).
There were 25 different J14 sequence types identified. Four
J14 sequence types were common to both GAS and GCS/GGS
(J14.0, J14.2, J14.4, and J14.61), 15 were unique to GAS (in-
cluding J14.1), and 6 were unique to GCS/GGS (J14.46, J14.60,
J14.62, J14.63, J14.66, and J14.67). Of the 25 J14 sequence
types, 14 have not been described previously (J14.55 to J14.68,
inclusive). When the J14 sequence types at C3, C2, and C1
were combined to create “overall” J14 C-repeat types, there
were 29 overall J14 types among the 521 GAS isolates, and 12
overall J14 types among the 248 GCS/GGS isolates.
The most common J14 sequence type among the GAS iso-
lates was J14.1 (n  313 isolates, 60.1%), occurring in the C3
region alone in 4 GAS isolates, in both the C3 and C2 regions
in 298 GAS isolates, and in all three C-repeat regions in 11
GAS isolates. The second most common sequence type was
J14.0, which was found only in the C3 region (n 176, 33.8%).
Overall, J14.0 and J14.1 were recovered from 93.8% of GAS
isolates. With GCS/GGS isolates, the J14.0 was found in the
C3 region in all but two of the isolates (both stG354 isolates).
There was a clear relationship between emm subtype and J14
sequence type in the C3 region. Forty-three emm subtypes
contained J14.1 at C3, and 22 contained J14.0 at C3; no emm
subtype had both J14.0 and J14.1 types.
DISCUSSION
This study is the most comprehensive investigation of the
molecular epidemiology of beta-hemolytic streptococci in a
developing country reported to date. It is also the largest re-
port of J14 sequence typing. The emm profile of our isolates
was unique. A comparison of the 45 GAS emm types among
the pharyngeal isolates in our study with 51 emm types recov-
ered in a large surveillance study of pharyngitis in the United
States between 2000 and 2005 revealed that there were only 17
shared emm types, accounting for only 37% of pharyngeal
isolates in our study (37) (S. T. Shulman, R. R. Tanz, W.
Kabat, K. Kabat, J. Rippe, B. Beall, and J. B. Dale, presented
at the XVII Lancefield Symposium on Streptococci and Strep-
tococcal Diseases, Porto Heli, Greece, 2008). In contrast, 29 of
the 37 emm subtypes recovered from invasive isolates in our
study were also found among 89 emm types recovered from a
TABLE 3. emm subtypes recovered from GAS from the
pharynx only
emm
subtypea
No. recovered
(n  16) % Recovered
emm1-2.3* 5 31.3
emm14.4 3 18.8
emm39.4** 1 6.3
emm60.7** 1 6.3
emm63.3 1 6.3
emm87.0 1 6.3
emm110.0 1 6.3
st465.0*** 1 6.3
st5282.0 1 6.3
st11014.0 1 6.3
a *, emm1-2.3 is sufficiently divergent from emm1 to be considered a distinct
emm type; **, new subtype; ***, new type.
TABLE 4. emm subtypes recovered from GAS from impetigo
lesions only
emm
subtypea
No. recovered
(n  81) % Recovered
emm4.5 5 6.2
emm11.1 1 1.2
emm19.4 3 3.7
emm39.1 12 14.8
emm52.1 6 7.4
emm53.0 2 2.5
emm55.0 1 1.2
emm57.0 2 2.5
emm60.1 1 1.2
emm73.0 15 18.5
emm85.0 4 4.9
emm93.4* 1 1.2
emm89.11* 1 1.2
emm97.1 2 2.5
emm98.1 3 3.7
emm100.0 6 7.4
emm103.0 11 13.6
emm104.0 3 3.7
st4119.0 1 1.2
st9505.0 1 1.2
a *, new subtype.
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large surveillance study of invasive isolates in the United States
between 2000 and 2004. However, of the 10 most common
invasive emm types in the U.S. study, only two emm types were
also seen in Fiji (68.3% of all isolates versus 6%, respectively;
P  0.001).
The emm profile for Fiji was similar to that found for other
tropical countries, in that there was a much flatter distribution
of emm types, with less evidence of dominant types, compared
to profiles in industrialized nations. However, the emm profile
for Fiji was by no means identical to that for other tropical
countries. For example, when comparing our data to those
from a similar study in Ethiopia, only 24 out of 76 emm types
recovered from pharyngeal and impetigo swabs in Ethiopia
were also found in Fiji, accounting for 40.9% of Fiji isolates
(45). A similar study conducted with the Aboriginal population
of the Northern Territory of Australia found that 26 out of 60
emm types recovered from pharyngeal and impetigo swabs in
the Northern Territory were also found in isolates from Fiji,
accounting for 45.7% of Fiji isolates (23). Of note, 5 out of the
10 most common emm types recovered from pharyngeal swabs
from the Northern Territory and 7 of the 10 most common
emm types recovered from impetigo swabs were also seen
FIG. 2. J14 sequences in GAS, GCS, and GGS isolates recovered from Fiji. N.C.R., no C repeat. (A) J14 sequence types in GAS isolates (n 
521). (B) J14 sequence types in GCS and GGS isolates (n  248).
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among the Fiji isolates, accounting for 8% and 20% of Fiji
isolates, respectively.
There was a great deal of sharing of emm types between
pharyngeal and impetigo sites, with 55% of emm subtypes
being found both in isolates from the pharynx and impetigo
lesions and with emm subtypes associated with impetigo ac-
counting for 84.2% of all pharyngeal isolates. There was even
evidence of sharing of emm subtypes between the pharynx and
the skin in individual children. Classical reports of GAS epi-
demiology from the United States described a division among
serotypes such that some serotypes had the potential to infect
mainly the pharynx, while others the potential to infect mainly
the skin (1, 7). However, these reports also described a signif-
icant number of serotypes that appeared to have the potential
to equally infect both sites. These classical reports were fol-
lowed by the classification of GAS isolates into class I types
that are serum opacity factor-negative and associated with
pharyngeal infection and class II types that are serum opacity
factor-positive and associated with impetigo infection (4). The
molecular basis of this division is derived from sequencing of
the C-repeat region (4) and corresponds to J14.0 and J14.1
sequence types, respectively (47). We did not find a statistically
significant association between clinical site tropism and J14.0
and J14.1 sequence types in the C3-repeat region in GAS
isolates, suggesting that many of the isolates in our study are
able to move freely from skin to pharynx. This is in concert
with findings by other authors in tropical settings where impe-
tigo GAS strains predominate and where these skin strains
account for the majority of pharyngeal GAS isolates (23, 40).
However, the phenomenon is not isolated to tropical settings;
the sequence of the spread of GAS from normal skin to im-
petigo to the throat has previously been described for temper-
ate zones (10).
The profile of J14 sequence types in our study showed some
similarities to the profile found in a study of 37 GAS isolates
from northern India (47). In the study from India, investigators
observed that J14.0 and J14.1 were the most common J14
sequence types recovered and that J14.0 was found only in the
C3 region. However, there were also differences between the
two studies, including a greater number of J14 types in the C3
region in our study (nine versus two).
Compared to a study of emm sequence typing of GCS/GGS
pharyngeal isolates in the Northern Territory of Australia in
which there were 24 emm subtypes identified among 257 iso-
lates, there was a high diversity among the pharyngeal isolates
in our study (46 emm subtypes among 233 isolates) (22). The
high degree of throat tropism of GCS/GGS isolates in our
study, which was also found in the Australian study, was strik-
ing. The finding of emm12 among GCS/GGS pharyngeal and
impetigo isolates was of particular interest. While it is not
uncommon to identify GAS isolates with emm types normally
associated with GCS/GGS (22), it is rare to find emm types
associated with GAS among GCS/GGS isolates. An exception
to this is emm12; GGS isolates with type M12 antigen from
both impetigo and throat cultures were first described for
strains isolated in Trinidad in the 1960s (20). The explanation
for this phenomenon appears to be that there is horizontal
transfer of the emm12 gene between GAS and GCS/GGS (39).
Interestingly, there were no emm12 GAS isolates in our study.
All of these findings have significant implications for GAS
vaccine design and development. When comparing the emm
profile of isolates in our study to that of the 26-valent vaccine
currently in clinical trials, only 26% of isolates would be po-
tentially covered in the current formulation of the vaccine.
Moreover, the lack of dominant types in our study suggests
that it would be difficult to target common epitopes. Further,
GCS and GGS isolates were also highly prevalent in our study,
and of the emm types found in our study among GCS and GGS
isolates, only one emm type, emm12, is included in the vaccine.
In our study 93.8% of GAS isolates and 99.3% of GCS/GGS
isolates that underwent J14 sequence typing contained either
J14.0 or J14.1. These are encouraging data for a J8 vaccine,
because it is known that antibodies against the J8 peptide
provide cross-protection against GAS strains containing J14.0
and J14.1. All of the remaining isolates contained J14.2; based
upon amino acid sequence, it is likely that cross-protection by
a J8 vaccine will be afforded to isolates containing the J14.2
sequence, as there is only a one-amino-acid difference between
J14.1 and J14.2 and a two-amino-acid difference between J14.0
and J14.2. In addition, antibodies raised against the J14.0 pep-
tide in mice have been shown to opsonize GAS strains that
contain J14.2 (47). An additional advantage of a J8 vaccine
may be potential cross-protection against GCS/GGS isolates;
all except two of the GCS/GGS isolates in our study contained
J14.0.
Our data confirm that the molecular epidemiology of GAS is
very different in this tropical setting from that found in tem-
perate industrialized countries. These findings suggest that
there may be some difficulties with a multiple emm-specific
GAS vaccine approach and that a conserved epitope strategy,
such as the J8 vaccine, may be more appropriate.
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